AML: Distribution of Aberrant Phenotypes at Diagnosis
| Aberrant Phenotypes (n = 53) . | No. of Cases (%) . | Total % . |
|---|---|---|
| Cross-lineage antigen expression (n = 16) | ||
| CD2 | 9 (17%) | |
| CD5 | 1 (2%) | |
| CD7 | 5 (9%) | 30% |
| CD19 | 2 (4%) | |
| CD22 | 1 (2%) | |
| Antigen overexpression (n = 5) | ||
| CD33 | 1 (2%) | |
| CD34 | 2 (4%) | 9% |
| CD117 | 1 (2%) | |
| HLADR | 2 (4%) | |
| Aberrant light-scatter patterns (n = 18) | ||
| CD2/high FSC/SSC | 8 (15%) | |
| CD7/high FSC/SSC | 5 (9%) | |
| CD13/low FSC/SSC | 5 (9%) | |
| CD14/low FSC/SSC | 1 (2%) | |
| CD15/low FSC/SSC | 2 (4%) | 34% |
| CD19/high FSC/SSC | 1 (2%) | |
| CD33/low FSC/SSC | 3 (6%) | |
| CD34/high FSC/SSC | 2 (4%) | |
| CD117/high FSC/SSC | 3 (6%) | |
| Asynchronous antigen expression (n = 44) | ||
| CD34+CD117+CD11b+ | 4 (8%) | |
| CD34+CD117+CD56+ | 2 (4%) | |
| CD34+CD33+HLADR− | 5 (9%) | |
| CD34+CD33−CD13+ | 10 (19%) | |
| CD34+CD11b+ | 4 (8%) | |
| CD34+CD56+ | 3 (6%) | |
| CD34+CD14+ | 2 (4%) | |
| CD34+CD33+CD13− | 1 (2%) | |
| CD34+CD15+CD117− | 4 (8%) | |
| CD34−CD15+CD117+ | 3 (6%) | 83% |
| CD34+CD117+CD13+HLADR− | 1 (2%) | |
| CD34+CD117+CD33+HLADR− | 11 (21%) | |
| CD117+CD33+HLADR− | 18 (34%) | |
| CD117+CD33+CD13− | 1 (2%) | |
| CD117+CD11b+ | 7 (13%) | |
| CD117+CD56+ | 3 (6%) | |
| CD34−CD14−CD15−CD33+ | 10 (19%) | |
| CD15+CD13−HLADR+ | 2 (4%) | |
| CD14+CD13−HLADR+ | 1 (2%) |
| Aberrant Phenotypes (n = 53) . | No. of Cases (%) . | Total % . |
|---|---|---|
| Cross-lineage antigen expression (n = 16) | ||
| CD2 | 9 (17%) | |
| CD5 | 1 (2%) | |
| CD7 | 5 (9%) | 30% |
| CD19 | 2 (4%) | |
| CD22 | 1 (2%) | |
| Antigen overexpression (n = 5) | ||
| CD33 | 1 (2%) | |
| CD34 | 2 (4%) | 9% |
| CD117 | 1 (2%) | |
| HLADR | 2 (4%) | |
| Aberrant light-scatter patterns (n = 18) | ||
| CD2/high FSC/SSC | 8 (15%) | |
| CD7/high FSC/SSC | 5 (9%) | |
| CD13/low FSC/SSC | 5 (9%) | |
| CD14/low FSC/SSC | 1 (2%) | |
| CD15/low FSC/SSC | 2 (4%) | 34% |
| CD19/high FSC/SSC | 1 (2%) | |
| CD33/low FSC/SSC | 3 (6%) | |
| CD34/high FSC/SSC | 2 (4%) | |
| CD117/high FSC/SSC | 3 (6%) | |
| Asynchronous antigen expression (n = 44) | ||
| CD34+CD117+CD11b+ | 4 (8%) | |
| CD34+CD117+CD56+ | 2 (4%) | |
| CD34+CD33+HLADR− | 5 (9%) | |
| CD34+CD33−CD13+ | 10 (19%) | |
| CD34+CD11b+ | 4 (8%) | |
| CD34+CD56+ | 3 (6%) | |
| CD34+CD14+ | 2 (4%) | |
| CD34+CD33+CD13− | 1 (2%) | |
| CD34+CD15+CD117− | 4 (8%) | |
| CD34−CD15+CD117+ | 3 (6%) | 83% |
| CD34+CD117+CD13+HLADR− | 1 (2%) | |
| CD34+CD117+CD33+HLADR− | 11 (21%) | |
| CD117+CD33+HLADR− | 18 (34%) | |
| CD117+CD33+CD13− | 1 (2%) | |
| CD117+CD11b+ | 7 (13%) | |
| CD117+CD56+ | 3 (6%) | |
| CD34−CD14−CD15−CD33+ | 10 (19%) | |
| CD15+CD13−HLADR+ | 2 (4%) | |
| CD14+CD13−HLADR+ | 1 (2%) |
The total number of aberrant cases is 46. The number of cases with 1 aberrancy is 26 cases, with 2 aberrancies is 5 cases, with 3 aberrancies is 13 cases, and with 4 aberrancies is 2 cases.